Cargando…

Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes

Chronic myeloid leukemia (CML) patients with complex chromosomal translocations as well as non-compliant CML patients often demonstrate short-lived responses and poor outcomes on the current therapeutic regimes using Imatinib and its variants. It has been derived so far that leukemic stem cells (LSC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anusha, Dalal, Hamza, Subramanian, Sitalakshmi, V. P., Snijesh, Gowda, Divya A., H., Krishnamurthy, Damodar, Sharat, Vyas, Neha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952724/ https://www.ncbi.nlm.nih.gov/pubmed/33707419 http://dx.doi.org/10.1038/s41419-021-03542-w

Ejemplares similares

Oligomerization and endocytosis of Hedgehog is necessary for its efficient exovesicular secretion
por: Parchure, Anup, et al.
Publicado: (2015)

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
por: Ko, Tun Kiat, et al.
Publicado: (2014)

The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis
por: Xu, Jinyun, et al.
Publicado: (2017)

Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines
por: Wang, Qian, et al.
Publicado: (2017)

Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in gorlin syndrome
por: Chaudhary, Sandeep C., et al.
Publicado: (2015)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia
por: Yu, Nae, et al.
Publicado: (2017)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

BEX1 Promotes Imatinib-Induced Apoptosis by Binding to and Antagonizing BCL-2
por: Xiao, Qian, et al.
Publicado: (2014)

The transcriptional landscape of Shh medulloblastoma
por: Skowron, Patryk, et al.
Publicado: (2021)

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Relative quantification of BCL2 mRNA for diagnostic usage needs stable uncontrolled genes as reference
por: Dwivedi, Nehanjali, et al.
Publicado: (2020)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

A Shh-Foxf-Fgf18-Shh Molecular Circuit Regulating Palate Development
por: Xu, Jingyue, et al.
Publicado: (2016)

Cysteine‐rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl‐2 pathway
por: Song, Yanfang, et al.
Publicado: (2019)

Shh is out on a limb
por: LeBrasseur, Nicole
Publicado: (2004)

Translational selection on SHH genes
por: Hajjari, Mohammadreza, et al.
Publicado: (2010)

Shh-mediated degradation of Hhip allows cell autonomous and non-cell autonomous Shh signaling
por: Kwong, Lina, et al.
Publicado: (2014)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
por: Russo, D, et al.
Publicado: (2015)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

The Shh Signaling Pathway Is Upregulated in Multiple Cell Types in Cortical Ischemia and Influences the Outcome of Stroke in an Animal Model
por: Jin, Yongmin, et al.
Publicado: (2015)

Uncontrolled neovascular glaucoma – an alarming manifestation of chronic myeloid leukemia on imatinib therapy – a case report and review of literature
por: Roop, Prakhyat, et al.
Publicado: (2019)

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
por: Go, Seong Woo, et al.
Publicado: (2013)

Decreased expression of microRNA-214 contributes to imatinib mesylate resistance of chronic myeloid leukemia patients by upregulating ABCB1 gene expression
por: Jin, Jing, et al.
Publicado: (2018)

Evasion of cell senescence in SHH medulloblastoma
por: Tamayo-Orrego, Lukas, et al.
Publicado: (2016)

Upregulation of LINC01426 promotes the progression and stemness in lung adenocarcinoma by enhancing the level of SHH protein to activate the hedgehog pathway
por: Liu, Xiaoli, et al.
Publicado: (2021)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia
por: Zhang, Tianzhuo, et al.
Publicado: (2020)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_f7k6gm3sjvvbkb5jb7fs1ph1c0